查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1316476

癌症免疫療法藥物研發發現外包市場：按癌症類型、藥物類型、服務類型分類 - 全球預測 2023-2030

Cancer Immunotherapy Drug Discovery Outsourcing Market by Cancer Type, Drug Type, Service Type - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球癌症免疫療法藥物研發外包市場將達到16.0191億美元，複合年成長率為15.52%，大幅成長，2030年將達到驚人的44.1696億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球癌症免疫療法藥物研發外包市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對整體收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解自家公司在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.癌症免疫治療藥物研發外包的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球癌症免疫療法藥物研發發現外包市場的阻礙因素和影響是什麼？

3. 在預測期內，全球癌症免疫治療藥物研發外包市場需要投資哪些產品/細分市場/用途/領域？

4.全球癌症免疫治療藥物藥物研發外包市場的競爭策略為何？

5.全球癌症免疫治療藥物藥物研發外包市場的技術趨勢和法律規範是什麼？

6.全球癌症免疫治療藥物藥物研發外包市場主要供應商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入全球癌症免疫療法藥物研發外包市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症盛行率上升
      • 提高醫生和病人對免疫治療的認知
      • 增加對開發癌症治療方法的投資
    • 抑制因素
      • 藥物開發和治療費用昂貴
    • 機會
      • 增加臨床試驗以開發有效的癌症免疫療法
      • 擴大與製藥公司的 CDMO 合作
    • 任務
      • 嚴格的政府法規和指導方針
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 癌症免疫治療藥物研發外包市場：按癌症類型

  • 介紹
  • 胸部
  • 大腸直腸
  • 頭部和頸部
  • 肺
  • 黑色素瘤
  • 子房
  • 胰臟
  • 攝護腺

第7章 癌症免疫治療藥物研發外包市場：按藥物類型

  • 介紹
  • 免疫調節劑
  • 單株抗體
  • 溶瘤病毒療法和癌症疫苗

第8章 癌症免疫治療藥物研發外包市場：依服務類型

  • 介紹
  • 基於細胞的檢測
  • 鉛篩選與表徵
  • 目標識別與檢驗

第9章 北美和南美癌症免疫療法藥物研發發現外包市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太癌症免疫治療藥物研發發現外包市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲癌症免疫療法藥物研發外包市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-205091A88728

The Global Cancer Immunotherapy Drug Discovery Outsourcing Market is forecasted to grow significantly, with a projected USD 1,601.91 million in 2023 at a CAGR of 15.52% and expected to reach a staggering USD 4,416.96 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Immunotherapy Drug Discovery Outsourcing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Cancer Type, market is studied across Breast, Colorectal, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, and Prostate. The Lung is projected to witness significant market share during forecast period.

Based on Drug Type, market is studied across Immunomodulators, Monoclonal Antibodies, and Oncolytic Viral Therapies & Cancer Vaccines. The Immunomodulators is projected to witness significant market share during forecast period.

Based on Service Type, market is studied across Cell-based Assays, Lead Screening & Characterization, and Target Identification & Validation. The Lead Screening & Characterization is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Drug Discovery Outsourcing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

6. What is the market share of the leading vendors in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Drug Discovery Outsourcing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type, 2022 vs 2030
  • 4.3. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type, 2022 vs 2030
  • 4.4. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type, 2022 vs 2030
  • 4.5. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Increasing awareness regarding immunotherapy among physicians and patients
      • 5.1.1.3. Increasing investments for the development of cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in clinical trials for development of efficient cancer immunotherapy
      • 5.1.3.2. Increasing CDMO collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and guidelines
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast
  • 6.3. Colorectal
  • 6.4. Head and Neck
  • 6.5. Lung
  • 6.6. Melanoma
  • 6.7. Ovarian
  • 6.8. Pancreatic
  • 6.9. Prostate

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Immunomodulators
  • 7.3. Monoclonal Antibodies
  • 7.4. Oncolytic Viral Therapies & Cancer Vaccines

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Cell-based Assays
  • 8.3. Lead Screening & Characterization
  • 8.4. Target Identification & Validation

9. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
  • FIGURE 5. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
  • FIGURE 9. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OVARIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PANCREATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRAL THERAPIES & CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD SCREENING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 149. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 150. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET LICENSE & PRICING